AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05164978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEP combine with PD-1 antibody
Description: Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
Study NCT04808583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLH with uterine artery ligation at its origin at the beginning of the operation
Description: After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery
Study NCT04808583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional TLH with uterine artery ligation after the cornual pedicles
Description: Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
Study NCT06492629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.
Study NCT06492629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
Study NCT06211023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1921
Description: SHR-1921
Study NCT06211023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 4
Study NCT06211023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 5
Study NCT06211023 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: platinum-based doublet chemotherapy
Description: platinum-based doublet chemotherapy
Study NCT04939467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone 267 mg Oral Tablet
Description: Fixed sequence use of active product, TID
Study NCT04939467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg Oral Capsule
Description: Fixed sequence use of active product, BID
Study NCT04939467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409 750 mg Oral Tablet
Description: Fixed sequence use of active product, QD
Study NCT05105256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
Study NCT05105256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
Study NCT06481787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan Fumarate
Description: Vonorasan fumarate is taken 30min before breakfast and dinner.
Study NCT06481787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuojin Pills
Description: Zuojin Pills should be taken 30min after breakfast and dinner.
Study NCT05426746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-100
Description: intravenous infusion of drug substance diluted in 0.9% normal sterile saline
Study NCT05426746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: intravenous infusion of placebo (0.9% normal sterile saline)
Study NCT04785417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: touch screen tablet
Description: traditional occupational therapy in addition to games on tablet
Study NCT05707221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste
Description: mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
Study NCT05707221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cleaning removable acrylic appliance with cleansing tablet
Description: chemical cleaning by patient for 7 days with cleansing tablet
Study NCT05707221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combination of mechanical and chemical cleaning
Description: cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
Study NCT06332222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart Cherry
Description: 7 day supplementation
Study NCT06332222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 day supplementation
Study NCT05609669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CADENCE program
Description: The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.
Study NCT05869799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vigiis 101 Lactobacillus Capsules
Description: Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
Study NCT05869799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Maltodextrin was used as a placebo
Study NCT05049005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simplified dietary tracking
Description: Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
Study NCT05049005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simplified dietary tracking
Description: Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
Study NCT06069388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diaphragm technique
Description: The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
Study NCT06069388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
Study NCT06069388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
Study NCT05252858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nCAP Signal Relief Patch
Description: nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
Study NCT05252858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
Study NCT05252858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
Study NCT05310877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-Affirmation
Description: Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
Study NCT04626323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: 1. Pneumoperitoneum closed with Veress needle~2. Identification of Treitz angle~3. Measurement of biliary loop (50 cm)~4. Bowel transection with linear stapler (white load)~5. Measurement of the alimentary limb (100 cm)~6. Laterolateral Entero-anastomoses (white load)~7. Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~8. Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~9. Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes
Study NCT04626323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
Study NCT04626323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
Study NCT05314309 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of two tests (FIT and mtFIT) in the same bowel movement
Description: Invitees for the Dutch National CRC screening program will be randomly selected by the Screening Organization and invited to participate in this study, where next to the current FIT, participants will also perform the mtFIT in one bowel movement. Both tests will be analysed and if one of the two test results is positive, the individual will be referred for colonoscopy.
Study NCT05285111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reconnecting to Internal Sensations and Experiences
Description: The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
Study NCT05285111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Habits
Description: The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating.
Study NCT05285839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupixent
Description: dupilumab 300mg
Study NCT05433610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Ventilation
Description: Exercise capacity testing using the device
Study NCT05433610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Ventilation
Description: Exercise capacity testing using the device
Study NCT04689542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-To-Stand test
Description: The 1-minute sit-to-stand test will be realized with or without a surgical facemask covering the face of the patient with COVID-19
Study NCT06432387 — intervention group
Intervention type: OTHER
Intervention: Patients undergoing complex thoraco-abdominal aortic aneurysm repair
Description: Patients undergoing complex thoraco-abdominal aortic aneurysm repair
Study NCT04748718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based injury prevention program
Description: \~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
Study NCT06026436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: 12-24 hours after P2Y12 ADP receptor loading dose (LD)
Study NCT06026436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: 1 month after Percutaneous Coronary Intervention (PCI)
Study NCT04927910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ture self-acupressure
Description: 8-week intervention of self-acupressure on acupoints
Study NCT04927910 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham self-acupressure
Description: 8-week intervention of self-acupressure on non-acupoints
Study NCT04927910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: routine care by hospitals
Study NCT05719181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Description: Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .
Study NCT05482802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An active training tool on weight bias and knowledge about obesity
Description: The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
Study NCT05482802 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: A short-written document on obesity
Description: A short-written document on obesity which will be based on current literature.
Study NCT06450769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia juice
Description: 100% aronia juice, 100 mL/day, twelve-week follow-up
Study NCT06450769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: An individually planned nutrition program suitable for the energy-restricted Mediterranean diet
Study NCT06450769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: An individually planned nutrition program suitable for the energy-restricted low-fat diet
Study NCT05890079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal transversus abdominis plane block
Description: External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
Study NCT05890079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External oblique intercostal plane block
Description: External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
Study NCT05580016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Soluble Urokinase Plasminogen Activation Receptor measurement
Description: In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.
Study NCT05885932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor
Description: All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
Study NCT05885932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and clopidogrel or ticagrelor
Description: All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
Study NCT05885932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mono anti-platelet therapy
Description: mono anti-platelet therapy
Study NCT05379920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Volume Aerobic Exercise
Description: Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
Study NCT05379920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Volume Aerobic Exercise
Description: Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
Study NCT05379920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Volume Aerobic Exercise
Description: Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
Study NCT05379920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Volume Aerobic Exercise
Description: Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
Study NCT04741048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI624 Slim 20 Electrode
Description: Cochlear Ltd CI624 cochlear implant with Slim 20 Electrode
Study NCT05374096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Chosen Music
Description: Music played into headphones.
Study NCT05374096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Silence into headphones.